Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: A review of recent clinical studies

Current Alzheimer Research

Volumn 7, Issue 1, 2010, Pages 67-73

  Darreh Shori, T ^a   Soininen, H ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cerebrospinal fluid; Cholinesterase inhibitors

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; UPREGULATION;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; HUMANS;

EID: 77649234636     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510790274455     Document Type: Article

References (35)

1. Davies P and Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403 (1976).
2. Darvesh S, Grantham DL and Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 393: 374-390 (1998).
3. Mesulam M, Guillozet A, Shaw P and Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9: 88-93 (2002).
4. Lane RM, Potkin SG and Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9: 101-124 (2006).
5. Darvesh S and Hopkins DA. Differential distribution of butyrylcho-linesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 463: 25-43 (2003).
6. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17: 159-165 (2001).
7. Masson P, Froment MT, Ribes F, Nachon F and Lockridge O. Substrate activation in acetylcholinesterase induced by low pH or mutation in the pi-cation subsite. Biochim Biophys Acta 1594: 313-324 (2002).
8. Masson P, Xie W, Froment MT, Levitsky V, Fortier PL, Albaret C, et al. Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta 1433: 281-293 (1999).
9. Chubb IW, Goodman S and Smith AD. Is acetylcholinesterase secreted from central neurons into the cerebral fluid? Neuroscience 1: 57-62 (1976).
10. Lane RM, Kivipelto M and Greig NH. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27: 141-9 (2004).
11. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49: 279-288 (2001).
12. Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L and Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 300: 157-160 (2001).
13. Nordberg A, Amberla K, Shigeta M, Lundqvist H, Viitanen M, Hellström-Lindahl E, et al. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 12: 228-237 (1998).
14. Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 19: 513-521 (1999).
15. Amici S, Lanari A, Romani R, Antognelli C, Gallai V and Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mech Ageing Dev 122: 2057-2062 (2001).
16. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 23(Suppl 2): S95-S96 (2002).
17. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59: 563-572 (2002).
18. Darreh-Shori T, Hellström-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H and Nordberg A. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem 88: 1102-1113 (2004).
19. Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellström-Lindahl E, Andreasen N, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 113: 1791-1801 (2006).
20. Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 29: 168-184 (2008).
21. Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6: 3-13 (2009).
22. Gauthier S. Long-term efficacy of cholinesterase inhibitors. Brain Aging 2: 9-22 (2002).
23. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1: CD005593 (2006).
24. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21: 1317-1327 (2005).
25. Sternfeld M, Shoham S, Klein O, Flores-Flores C, Evron T, Idelson GH, et al. Excess "read-through" acetylcholinesterase attenuates but the "synaptic" variant intensifies neurodeterioration correlates. Proc Natl Acad Sci USA 97: 8647-8652 (2000).
26. Shohami E, Kaufer D, Chen Y, Seidman S, Cohen O, Ginzberg D, et al. Antisense prevention of neuronal damages following head injury in mice. J Mol Med 78: 228-236 (2000).
27. Kaufer D, Friedman A, Seidman S and Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393: 373-377 (1998).
28. Shapira M, Grant A, Korner M and Soreq H. Genomic and transcriptional characterization of the human ACHE locus: complex involvement with acquired and inherited diseases. Isr Med Assoc J 2: 470-473 (2000).
29. Cohen O, Erb C, Ginzberg D, Pollak Y, Seidman S, Shoham S, et al. Neuronal overexpression of "readthrough" acetylcholinesterase is associated with antisense-suppressible behavioral impairments. Mol Psychiatry 7: 874-885 (2002).
30. Inestrosa NC and Alarcon R. Molecular interactions of acetylcholinesterase with senile plaques. J Physiol Paris 92: 341-344 (1998).
31. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O and Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 103: 8628-8633 (2006).
32. Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, Schuppli D, et al. Changes in readthrough acetylcholinesterase expression modulate amyloid-β pathology. Brain 131: 109-119 (2008).
33. Shanks M, Kivipelto M, Bullock R and Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin 25: 2439-2446 (2009).
34. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE ε4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 24: 392-400 (2009).
35. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63: 621-631 (2008).